Company: BIVIW
Filing Date: 2025-09-25
Form Type: DEF 14A
Source: 0001520138-25-000287
Chunk: 13

Company: BIOVIE INC.
Filing Date: 2025-09-25
Form: DEF 14A
Chunk 13
---
, President and Chief Executive Officer                                                                                                 |     |     2016 |
| Kameel Farag    |     |  47 |     | Director and Member of the Audit Committee                                                                                                      |     |     2025 |
| Sigmund Rogich  |     |  81 |     | Director, Chairman of the Nominating and Corporate Governance Committee and Member of the Compensation Committee                                |     |     2020 |
| Michael Sherman |     |  66 |     | Director, Chairman of the Compensation Committee, Member of the Audit Committee and Member of the Nominating and Corporate Governance Committee |     |     2017 |

Dr. Amy Chappellhas served as a director of the Company since
2025. Since 2024, she has served as CMO of Solaxa Inc., where she oversees clinical development of novel therapies for ataxia and nerve
repair. Prior to that, Dr. Chappell was a clinical trials and neurology consultant for various companies from 2021 to 2024. From 2020
to 2021, she was CMO of Eliem Therapeuetics, assisting it through a successful initial public offering and advancing programs in epilepsy
and mood disorders. Dr. Chappell has also served over 25 years at Eli Lilly & Co., where she played a central role in developing and
gaining US Food and Drug Administration (FDA) approvals for multiple central nervous system indications, including for Cymbalta® in
fibromyalgia and musculoskeletal pain. Dr. Chappell holds a BA from Antioch College and an MD from Indiana University School of Medicine.
She also holds numerous patents, has authored over 100 peer-reviewed publications and presentations, and remains a Fellow of the American
Academy of Neurology.

| -8- |

Dr. Chappell’s qualifications to serve on our Board of Directors
are primarily based on her decades of experience in clinical neuroscience and drug development.

Mr. James Lang, Chairman of the Board of Directors since 2023 and
has served as the Company’s director since 2016. He is currently CEO of EVERSANA, the leading commercialization services company
for the life sciences industry. In five years since he founded EVERSANA, it is now over $1B in revenue, with more than 7,000 employees
across 40 global locations. He formerly served as the CEO of Decision Resources Group (DRG